Overview

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Status:
Not yet recruiting
Trial end date:
2027-01-15
Target enrollment:
Participant gender:
Summary
A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.
Phase:
Early Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Yake Biotechnology Ltd.